TAVO101

Phase 2Small molecule

TTavotek Biotherapeutics

TAVO101 is one of 25 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisActive, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Elidel

Bayer

Phase 3

4 2

LNK01001

LLynk Pharmaceuticals Co., Ltd

Phase 3

2 3

Adquey

AAcrotech Biopharma Inc.

Phase 3

2 4

EBGLYSS

Eli Lilly

Preclinical

23 5

Cibinqo

Pfizer

Preclinical

11 6

Product 0405

FFougera Pharmaceuticals Inc.

Phase 3

3 7

Prograf

VVeloxis Pharmaceuticals

Preclinical

18 8

Stapokibatrt

KKeymed Biosciences Co.Ltd

Phase 3

2 9

Adtralza

LEO Pharma

Preclinical

15 10

V0034CR01B

PPierre Fabre Medicament

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atopic Dermatitis1 trial

A Study of TAVO101 in Atopic Dermatitis Patients

Active, not recruiting·TTavotek Biotherapeutics·Phase 2·NCT06176040·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TAVO101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAVO101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAVO101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tavotek Biotherapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTavotek Biotherapeutics

TAVO101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News